CBIO vs KMB · rev $1.0M vs P/E 19, rev $8.35B
Crescent Biopharma, Inc. (CBIO) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Crescent Biopharma, Inc. (CBIO) is a biotechnology company listed on NASDAQ.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Latest reported CBIO revenue for 2026-06-30 was $1.0M. Net income was -$48.1M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. CBIO currently screens at market cap $491.3M.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
CBIO currently screens at market cap $491.3M. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the CBIO and KMB stock pages for the full models.
Not investment advice.